BioNTech's cancer medicine shrinks tumors

At the end of 2019, the coronavirus (Covid-19), which broke out in China and spread all over the world, caused millions of people to lose their lives. Quarantines announced to prevent the virus, which mutated over time, worked, and the spread of the virus was stopped with vaccination efforts.

In this process, the names that attracted the attention of the whole world were the German biotechnology company BioNTech and Ugur Sahin and Ozlem Tureci. The two names that gave hope to the coronavirus are now on the agenda with an exciting event in another field.

Founders of biontech Ozlem Tureci and Ugur Sahin

German biotechnology firm BioNTech has reported progress in a drug against lung cancer, Anadolu reported. In a joint statement from BioNTech and OncoC4, the companies said encouraging signs have been received in phase ½ trials of OncoC4's antibody candidate ONC-392 (gotistobart) against lung cancer.

SHRUNK CANCER TUMORS IN 30 PERCENT

In the statement, it was stated that the antibody candidate shrunk cancer tumors in approximately 30 percent of the participants, while Phase 3 trials required for approval are planned to start in the third quarter of the year.

BioNTech and OncoC4 announced on March 20 that they will collaborate to co-develop and commercialize a lung cancer drug candidate. During the collaboration, BioNTech will make an upfront payment of $200 million to OncoC4 and will provide the company with various payments and tiered royalties during the collaboration period.

On the other hand, in recent weeks, the European Union (EU) and BioNTech-Pfizer agreed to reduce the amount and extend the delivery time in the Covid-19 vaccine purchase contract they made during the pandemic.

Source: Anadolu Agency